BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Proteon Adds $15M; Getting Closer to Novartis Option
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Proteon Adds $15M; Getting Closer to Novartis Option
Aug. 15, 2011
By
Jennifer Boggs
No Comments
About four months after kicking off a Phase II study of lead product PRT-201 , which, if positive, could entice a buyout bid from Novartis AG under a 2009 option deal, Proteon Therapeutics Inc. is padding its coffers with a $15.2 million financing.
BioWorld